Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Microsatellite pathologic score does not efficiently identify high microsatellite instability in colorectal serrated adenocarcinoma.

García-Solano J, Conesa-Zamora P, Carbonell P, Trujillo-Santos J, Torres-Moreno D, Rodriguez-Braun E, Vicente-Ortega V, Pérez-Guillermo M.

Hum Pathol. 2013 May;44(5):759-65. doi: 10.1016/j.humpath.2012.07.020. Epub 2012 Oct 22.

PMID:
23089493
2.

Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma.

Conesa-Zamora P, García-Solano J, García-García F, Turpin Mdel C, Trujillo-Santos J, Torres-Moreno D, Oviedo-Ramírez I, Carbonell-Muñoz R, Muñoz-Delgado E, Rodriguez-Braun E, Conesa A, Pérez-Guillermo M.

Int J Cancer. 2013 Jan 15;132(2):297-307. doi: 10.1002/ijc.27674. Epub 2012 Jun 28.

3.

Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas.

García-Solano J, Conesa-Zamora P, Carbonell P, Trujillo-Santos J, Torres-Moreno D D, Pagán-Gómez I, Rodríguez-Braun E, Pérez-Guillermo M.

Int J Cancer. 2012 Oct 15;131(8):1790-9. doi: 10.1002/ijc.27454. Epub 2012 Mar 14.

4.

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Roselló S, Langdon RB, Baselga J.

Clin Cancer Res. 2011 Oct 1;17(19):6304-12. doi: 10.1158/1078-0432.CCR-10-3336. Epub 2011 Aug 2.

5.

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, ONeil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA.

Cancer Res. 2011 Feb 1;71(3):675-85. doi: 10.1158/0008-5472.CAN-10-1030. Epub 2010 Dec 10.

6.

Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.

Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J.

Mol Cancer Ther. 2010 Oct;9(10):2844-52. doi: 10.1158/1535-7163.MCT-10-0299. Epub 2010 Aug 19.

7.

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F.

J Clin Oncol. 2010 Mar 1;28(7):1181-9. doi: 10.1200/JCO.2009.22.6043. Epub 2010 Jan 25.

PMID:
20100964
8.

Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.

Pérez Fidalgo JA, Roda D, Roselló S, Rodríguez-Braun E, Cervantes A.

Clin Transl Oncol. 2009 Dec;11(12):787-98. Review.

PMID:
20045785
9.

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A.

Ann Oncol. 2010 Jul;21(7):1537-45. doi: 10.1093/annonc/mdp549. Epub 2009 Nov 25.

PMID:
19940007
10.

Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer.

Cervantes A, Roselló S, Rodríguez-Braun E, Navarro S, Campos S, Hernández A, García-Granero E.

Ann Oncol. 2008 Sep;19 Suppl 7:vii266-72. doi: 10.1093/annonc/mdn438. Review. No abstract available.

PMID:
18790964
11.

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.

Martín-Martorell P, Roselló S, Rodríguez-Braun E, Chirivella I, Bosch A, Cervantes A.

Br J Cancer. 2008 Aug 5;99(3):455-8. doi: 10.1038/sj.bjc.6604530.

12.

The treatment of advanced gastric cancer: current strategies and future perspectives.

Cervantes A, Roselló S, Roda D, Rodríguez-Braun E.

Ann Oncol. 2008 Jul;19 Suppl 5:v103-7. doi: 10.1093/annonc/mdn321. Review. No abstract available.

PMID:
18611865
13.

Integrative decisions in rectal cancer.

Cervantes A, Rodríguez-Braun E, Navarro S, Hernández A, Campos S, García-Granero E.

Ann Oncol. 2007 Jul;18 Suppl 9:ix127-31. Review. No abstract available.

PMID:
17631565
14.

Molecular biology of gastric cancer.

Cervantes A, Rodríguez Braun E, Pérez Fidalgo A, Chirivella González I.

Clin Transl Oncol. 2007 Apr;9(4):208-15. Review.

PMID:
17462972
15.

[Phlegmasia cerulea dolens in patients with testicular carcinoma].

Chirivella González I, Teruel Casasús A, Magro Molina A, Insa Mollá A, Rodríguez Braun E, Cervantes Ruipérez A.

Actas Urol Esp. 2006 Nov-Dec;30(10):1043-5. Spanish.

PMID:
17253075
16.

A multimodality approach to localized rectal cancer.

Cervantes A, Chirivella I, Rodriguez-Braun E, Campos S, Navarro S, García Granero E.

Ann Oncol. 2006 Sep;17 Suppl 10:x129-34. Review. No abstract available.

PMID:
17018713

Supplemental Content

Loading ...
Support Center